Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 23 of 151

  1. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  2. B10 L-BPA Injection

    Heron Therapeutics

    Meningioma

    phase 2 small molecule completed

    1 trial

  3. B1791094

    Pfizer Australia Pty Ltd

    EROSIVE ESOPHAGITIS

    phase 2 small molecule active

    1 trial

  4. B1931036

    Pfizer Australia Pty Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  5. B7981118

    Pfizer Australia Pty Ltd

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  6. B7981119

    Pfizer Australia Pty Ltd

    HIDRADENITIS SUPPURATIVA

    phase 2 small molecule active

    1 trial

  7. BARICITINIB

    Pari Pharma GmbH

    Juvenile Dermatomyositis

    phase 2 small molecule active

    1 trial

  8. BAX 888

    Takeda

    Hemophilia A

    phase 2 small molecule completed

    1 trial

  9. BAX69 + infusional 5-FU/LV

    Takeda

    Metastatic Colorectal Cancer

    phase 2 mab terminated

    1 trial

  10. BAX69 Single-Route Arm

    Takeda

    Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites

    phase 2 mab terminated

    1 trial

  11. BAY 1021189

    Bayer AG

    Chronic heart failure with reduced ejection fraction

    phase 2 small molecule active

    1 trial

  12. BAY 1841788 for Hormone Naive Prostate Cancer

    Ningbo Cancer Hospital

    Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  13. BAY 2599023

    Bayer AG

    Hemophilia A

    phase 2 small molecule active

    1 trial

  14. BAY 3713372 Bayer for MTAP-deleted Solid Tumors

    Bayer AG

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  15. BAY 73-4506, AVELUMAB

    The George Institute

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  16. BAY 73-4506, BAY 734506

    Bayer AG

    Solid malignant tumors

    phase 2 small molecule active

    1 trial

  17. BAY1002670

    Bayer HealthCare AG

    Leiomyoma

    phase 2 small molecule completed

    1 trial

  18. BAY2757556 (Larotrectinib, Vitrakvi)

    Bayer HealthCare AG

    Solid Tumors Harboring NTRK Fusion

    phase 2 small molecule completed

    1 trial

  19. BB-1701-G000-205

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  20. BB-301: Dose escalation phase 1b cohort 1

    Benitec Biopharma

    Oculopharyngeal Muscular Dystrophy

    phase 2 gene therapy active

    1 trial

  21. BB-401

    Benitec Biopharma

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  22. BBI-20201001

    Bolt Biotherapeutics

    Advanced HER2-Expressing Solid Tumors.

    phase 2 small molecule active

    1 trial

  23. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  24. BC1 cell line

    BriaCell Therapeutics

    Breast Cancer

    phase 2 mab active

    1 trial

  25. BC45538

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  26. BCG (50mg/instillation) + N-803 (400 μg/instillation)

    Immunitybio Ireland Limited

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    1 trial

  27. BCG-RIS-01

    Fondazione Telethon ETS

    RIS (Radiologically Isolated Syndrome)

    phase 2 small molecule active

    1 trial

  28. BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma, Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  29. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  30. BCMA CART

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

    phase 2 small molecule active

    1 trial

  31. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  32. BCMA/CD3 bispecific antibody (CM336)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solitary Bone Plasmacytoma

    phase 2 small molecule active

    1 trial

  33. BCN04-DASA

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  34. BCN05-Bari

    MEDA Pharma GmbH & Co. KG

    Human immunodeficency virus

    phase 2 small molecule active

    1 trial

  35. BCT197

    Mereo BioPharma Group plc

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  36. BCT197

    Mereo BioPharma Group plc

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  37. BCT197 Part A

    Mereo BioPharma Group plc

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  38. BCX-1777

    Biocryst

    Leukemia, Lymphocytic

    phase 2 small molecule completed

    1 trial

  39. BCX17725

    Lacuna Pharma Pty Ltd

    Netherton Syndrome

    phase 2 small molecule active

    1 trial

  40. BCX1777-Tio-05-202

    Biocryst

    Leukemia

    phase 2 small molecule terminated

    1 trial

  41. BCX7353

    Biocryst

    Hereditary Angioedema (HAE)

    phase 2 small molecule completed

    2 trials

  42. BCX9930

    Biocryst

    Paroxysmal Nocturnal Hemoglobinuria

    phase 2 small molecule terminated

    3 trials

  43. BCX9930

    Biocryst

    Complement 3 Glomerulopathy

    phase 2 small molecule terminated

    1 trial

  44. BDB001

    Eikon Therapeutics

    Tumor, Solid

    phase 2 small molecule completed

    1 trial

  45. BDC-1001

    Bolt Biotherapeutics

    HER2-positive Solid Tumors

    phase 2 small molecule terminated

    1 trial

  46. BDC-1001

    Bolt Biotherapeutics

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  47. BDC-1001, PERTUZUMAB

    Bolt Biotherapeutics

    HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  48. BDC-4182

    Bolt Biotherapeutics

    Gastric Cancer Adenocarcinoma Metastatic

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.